AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update - Seite 3

Healthcare institutions across the United States have implemented various restrictions, and together with our own COVID-19 protocols, we therefore have dramatically reduced face-to-face experience with our existing, new and potential customers. In the majority of territories, our clinical and commercial support employees are no longer providing live case support at the hospitals.

• Our commercial team is leveraging digital tools to sustain our business, preserve relationships, and support continued excellent results for burn patients.
• Our RECELL System super users are more clinically experienced, and therefore more independent, than our newer users for whom we are deploying additional coaching, training, and assistance.
• Our field force continues to support cases and provide training virtually. For example, our case support staff are already successfully using online channels to provide virtual support for surgeons treating patients with the RECELL System (as needed).
  
  

The Company will continue to target new account initiations throughout the course of 2020; however, the rate of progression is likely to be impaired by the current operating environment.

• With COVID-19 protocols in place and limited onsite hospital presence for our personnel, it is possible that new account acquisition and new user uptake may be delayed or more graduated than would otherwise be the case.
• The cancellation of various professional meetings (e.g. the 2020 Annual American Burn Association Meeting in March) is disappointing and provides more limited access to existing and new customers than previously anticipated. The Company continues to pursue its communications and related strategies for abstracts, posters, and publications.
  
  

Investigational studies within the United States are largely being de-prioritized by hospitals and sponsors in order to not distract critical resources away from patients requiring COVID-19 treatment. While some of the Company’s study sites continue to search for patients to enroll, the Company largely expects there to be a pause in enrollment and site roll-out until the COVID-19 pandemic improves.

The Company is well-capitalized and does not currently require additional funding.

Corporate Presentation

An updated corporate presentation will also be available on the Company’s website later today.